Cell surface-dependent generation of angiostatin4.5

被引:26
作者
Wang, H [1 ]
Schultz, R [1 ]
Hong, J [1 ]
Cundiff, DL [1 ]
Jiang, K [1 ]
Soff, GA [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
关键词
D O I
10.1158/0008-5472.CAN-03-1862
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiostatin4.5 (AS4.5) is a naturally occurring human angiostatin isoform, consisting of plasminogen kringles 1-4 plus 85% of kringle 5 (amino acids Lys78 to Arg529). Prior studies indicate that plasminogen is converted to AS4.5 in a two-step reaction. First, plasminogen is activated to plasmin. Then plasmin undergoes autoproteolysis within the inner loop of kringle 5, which can be induced by a free sulfhydryl donor or an alkaline pH. We now demonstrate that plasminogen can be converted to AS4.5 in a cell membrane-dependent reaction. Actin was shown previously to be a surface receptor for plasmin(ogen). We now show that beta-actin is present on the extracellular membranes of cancer cells (PC-3, HT1080, and MDA-MB231), and beta-actin can mediate plasmin binding to the cell surface and autoproteolysis to AS4.5. In the presence of beta-actin, no small molecule-free sulfhydryl donor is needed for generation of AS4.5. Antibodies to actin reduced membrane-dependent generation of AS4.5 by 70%. In a cell-free system, addition of actin to in vitro-generated plasmin resulted in stoichiometric conversion to AS4.5. Annexin II and alpha-enolase have been reported to be plasminogen receptors, but we did not demonstrate a role for these proteins in conversion of plasminogen to AS4.5. Our data indicate that membrane-associated beta-actin, documented previously as a plasminogen receptor, is a key cell membrane receptor capable of mediating conversion of plasmin to AS4.5. This conversion may serve an important role in regulating tumor angiogenesis, invasion, and metastasis, and surface beta-actin may also serve as a prognostic marker to predict tumor behavior.
引用
收藏
页码:162 / 168
页数:7
相关论文
共 58 条
[1]   CARCINOMA OF THE UTERINE CERVIX FIGO STAGE I-B [J].
ADCOCK, LL ;
JULIAN, TM ;
OKAGAKI, T ;
JONES, TK ;
PREM, KA ;
TWIGGS, LB ;
POTISH, RA ;
PHILLIPS, GL .
GYNECOLOGIC ONCOLOGY, 1982, 14 (02) :199-208
[2]   The topology of plasminogen binding and activation on the surface of human breast cancer cells [J].
Andronicos, NM ;
Ranson, M .
BRITISH JOURNAL OF CANCER, 2001, 85 (06) :909-916
[3]   Effects of angiogenesis inhibitors on multistage carcinogenesis in mice [J].
Bergers, G ;
Javaherian, K ;
Lo, KM ;
Folkman, J ;
Hanahan, D .
SCIENCE, 1999, 284 (5415) :808-812
[4]   TUMOR INTERACTIONS WITH THE VASCULATURE - ANGIOGENESIS AND TUMOR-METASTASIS [J].
BLOOD, CH ;
ZETTER, BR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1032 (01) :89-118
[5]   ANGIOGENESIS - MARKER FOR NEOPLASTIC TRANSFORMATION OF MAMMARY PAPILLARY HYPERPLASIA [J].
BREM, SS ;
GULLINO, PM ;
MEDINA, D .
SCIENCE, 1977, 195 (4281) :880-882
[6]   PROGNOSTIC FACTORS ASSOCIATED WITH RADICAL HYSTERECTOMY FAILURE [J].
BURKE, TW ;
HOSKINS, WJ ;
HELLER, PB ;
BIBRO, MC ;
WEISER, EB ;
PARK, RC .
GYNECOLOGIC ONCOLOGY, 1987, 26 (02) :153-159
[7]   Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis [J].
Cao, RH ;
Wu, HL ;
Veitonmäki, N ;
Linden, P ;
Farnebo, J ;
Shi, GY ;
Cao, YH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5728-5733
[8]  
Cao YH, 2000, INT J MOL MED, V5, P547
[9]  
Castellino F. J., 1995, MOL BASIS THROMBOSIS, P495
[10]  
CESARMAN GM, 1994, J BIOL CHEM, V269, P21198